VB50.F ALBERT LABS INTL. CORP.
- Market cap
- EUR 372K
- P/E
- -
- P/B
- 17.00x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is VB50.F undervalued?
Graham numberThe Graham number of ALBERT LABS INTL. CORP. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ALBERT LABS INTL. CORP. fundamental analysis
No fundamental analysis for ALBERT LABS INTL. CORP. yet.
ALBERT LABS INTL. CORP. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ALBERT LABS INTL. CORP.
Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.
Full company profileALBERT LABS INTL. CORP. financial statements
ALBERT LABS INTL. CORP. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 |
|---|---|---|
| Income Statement | ||
| Revenue | 0.00 | 0.00 |
| Operating Income | -1.88M | -4.14M |
| EBITDA | -1.88M | -4.14M |
| Net Income | -1.88M | -7.06M |
| EPS | -0.03 | -0.10 |
| Balance Sheet | ||
| Total Assets | 358K | 164K |
| Total Liabilities | 860K | 529K |
| Shareholders' Equity | -503K | -365K |
| Cash & Short-term Investments | 76.7K | 79.1K |
| Cash Flow | ||
| Operating Cash Flow | -912K | -1.43M |
| Capital Expenditure | 142K | 64.3K |
| Free Cash Flow | -1.05M | -1.50M |
| Ratios | ||
| ROA | -525.2% | -4,310.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
ALBERT LABS INTL. CORP. dividends
ALBERT LABS INTL. CORP. has not paid dividends in the last 2 fiscal years.
Who owns ALBERT LABS INTL. CORP.
Ownership data of ALBERT LABS INTL. CORP. is not available yet.
ALBERT LABS INTL. CORP. company profile
- Company name
- ALBERT LABS INTL. CORP.
- Ticker
- VB50.F
- ISIN
- CA0127841041
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 201-6996 Merritt Avenue, Burnaby, BC, Canada, V5J 4R6
- Phone
- 778 819 0740
- Website
- albertlabs.com
About ALBERT LABS INTL. CORP.
Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.
ALBERT LABS INTL. CORP. management
4- Mr. Navchand JagpalActing CEO, CFO & Director · born 1968
- Mr. Santoke NaalChief Operating Officer
- Mr. Toby Campbell SorabjeeChief Communications Officer
- Dr. Malcolm Barratt-JohnsonChief Medical Officer